David J Vanderweele

List of Publications by Year
in descending order

30	1,242	471477 17	610883 24
papers	citations	h-index	g-index

31	31	31	2616
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. Clinical Cancer Research, 2021, 27, 429-437.	7.0	22
2	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. European Urology, 2021, 80, 746-757.	1.9	50
3	Trimodality treatment for muscle-invasive bladder cancer: an institutional experience. Advances in Radiation Oncology, 2021, 6, 100718.	1.2	0
4	Editorial Comment. Journal of Urology, 2021, 206, 628-629.	0.4	0
5	Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 2020, 1, 1041-1053.	13.2	45
6	EDITORIAL COMMENT. Urology, 2020, 146, 165-166.	1.0	0
7	Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. Molecular Cancer Therapeutics, 2020, 19, 1436-1447.	4.1	31
8	A case report of multiple primary prostate tumors with differential drug sensitivity. Nature Communications, 2020, 11, 837.	12.8	28
9	PARP inhibitors in prostate cancer: practical guidance for busy clinicians. Clinical Advances in Hematology and Oncology, 2020, 18, 808-815.	0.3	3
10	Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. European Urology Focus, 2019, 5, 416-424.	3.1	20
11	Past, Current, and Future of Immunotherapies for Prostate Cancer. Frontiers in Oncology, 2019, 9, 884.	2.8	89
12	Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?. Translational Andrology and Urology, 2019, 8, S91-S92.	1.4	0
13	mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 352.e25-352.e30.	1.6	4
14	AR Gain: Resistance Mechanism or Measure of Tumor Burden?. JCO Precision Oncology, 2019, 3, 1-2.	3.0	0
15	Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. European Urology Focus, 2019, 5, 433-442.	3.1	27
16	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
17	Circulating tumor cells capture disease evolution in advanced prostate cancer. Journal of Translational Medicine, 2017, 15, 44.	4.4	27
18	Precision management of localized prostate cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 505-515.	0.7	6

#	Article	IF	Citations
19	Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study. American Journal of Roentgenology, 2016, 206, 559-565.	2.2	48
20	Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer â€“ A Case Report. Frontiers in Oncology, 2015, 5, 169.	2.8	10
21	Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology, 2015, 86, 777-782.	1.0	26
22	Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue. American Journal of Translational Research (discontinued), 2015, 7, 1227-35.	0.0	7
23	Lowâ€grade prostate cancer diverges early from high grade and metastatic disease. Cancer Science, 2014, 105, 1079-1085.	3.9	46
24	Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. Journal of Translational Medicine, 2014, 12, 313.	4.4	37
25	Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 2009, 113, 2014-2021.	1.4	189
26	Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress inSaccharomyces cerevisiae. Yeast, 2005, 22, 641-652.	1.7	27
27	Mammalian Target of Rapamycin Promotes Vincristine Resistance through Multiple Mechanisms Independent of Maintained Glycolytic Rate. Molecular Cancer Research, 2005, 3, 635-644.	3.4	18
28	Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Molecular Cancer Therapeutics, 2004, 3, 1605-13.	4.1	79
29	Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Research, 2003, 63, 312-8.	0.9	130
30	Bcl-x Complements Saccharomyces cerevisiae Genes That Facilitate the Switch from Glycolytic to Oxidative Metabolism. Journal of Biological Chemistry, 2002, 277, 44870-44876.	3.4	59